Zentalis Pharmaceuticals (ZNTL) Total Non-Current Liabilities (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Total Non-Current Liabilities of $69.9 million for Q1 2026, down 20.66% year-over-year from $88.1 million in Q1 2025, and down 3.29% quarter-over-quarter from $72.3 million in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $69.9 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 20.66% year-over-year to $69.9 million; the TTM figure through Mar 2026 stood at $69.9 million (down 20.66% YoY), while the FY2025 annual figure was $72.3 million, down 21.71% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $69.9 million, down from $72.3 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $112.5 million in Q4 2023, with the low at $45.0 million in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $95.3 million (2024), against an average of $90.1 million.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities jumped 163.56% in 2022, then retreated 28.98% in 2025.
- Zentalis Pharmaceuticals' Total Non-Current Liabilities stood at $102.7 million in 2022, then rose by 9.6% to $112.5 million in 2023, then dropped by 17.97% to $92.3 million in 2024, then declined by 21.71% to $72.3 million in 2025, then declined by 3.29% to $69.9 million in 2026.
- Business Quant data shows ZNTL's Total Non-Current Liabilities at $69.9 million in Q1 2026, $72.3 million in Q4 2025, and $73.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | 71.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 71.18 Mn |
| Mar 31, 2026 | 69.89 Mn |
| Dec 31, 2025 | 72.26 Mn |
| Sep 30, 2025 | 73.88 Mn |
| Jun 30, 2025 | 76.71 Mn |
| Mar 31, 2025 | 88.08 Mn |
| Dec 31, 2024 | 92.30 Mn |
| Sep 30, 2024 | 95.33 Mn |
| Jun 30, 2024 | 108.01 Mn |
| Mar 31, 2024 | 97.41 Mn |
| Dec 31, 2023 | 112.52 Mn |
| Sep 30, 2023 | 102.18 Mn |
| Jun 30, 2023 | 97.66 Mn |
| Mar 31, 2023 | 101.89 Mn |
| Dec 31, 2022 | 102.67 Mn |
| Sep 30, 2022 | 100.46 Mn |
| Jun 30, 2022 | 95.03 Mn |
| Mar 31, 2022 | 45.03 Mn |
| Dec 31, 2021 | 89.03 Mn |
| Sep 30, 2021 | 41.09 Mn |